Clinical Trials Directory

This study uses a system called Hemanext ONE that keeps red blood cells in low oxygen. The study lasts about fourteen months. During the study, you will receive two kinds of blood transfusions. One kind uses low oxygen blood, and the other uses regular blood. The order is chosen by chance. Each type of transfusion lasts six months, with a two month break in between. At each visit, doctors will check your vital signs, do blood tests, and ask how you are feeling. There is also an optional visit one day after a transfusion for extra blood tests.

We are doing this study to find out if an experimental drug called etavopivat (the study drug) is a safe and effective option for children and adolescents who have SCD.

Many people with HIV want to breastfeed their babies, but until recently, the rules in the U.S. didn't allow this. There's a small risk of passing HIV to the baby, but we need more information to understand this better. This research will make a list of babies and how they are fed, talk to families about why they choose certain ways to feed their babies, and test breast milk and blood to see if the HIV that can't be found in the blood is also not in the breast milk.

We are doing this study to find out if an experimental drug called abatacept (the study drug) is a safe and effective option to help prevent graft-versus-host (GVHD) disease for people who get an omidubicel hematopoietic stem cell transplant to treat blood cancer. Omidubicel is a recently approved (2023) stem cell transplantation that uses modified umbilical cord blood. This new method of stem cell transplantation helps patients' immune systems recover more quickly after intensive chemotherapy.

After joining the study, each person will have several checkups. These include the first visit, the ablation procedure, and a visit before going home. There will also be a phone call about one week later, a visit around one month later, and visits at three months, six months, and twelve months. These visits help doctors check how the heart is doing over time.

If you agree to be in the study, you will have 1 study visit that will last about 4 hours. The visit will include asking questions about your medical history, vital signs, pulmonary function tests (PFTs) and an MRI (magnetic resonance image) of the chest with inhaled Xenon gas. Someone from the study team will contact you about 24 hours after your study visit.

We are doing this study to analyze biomarker responses to different drug regimens used for people who have HER2- and HER2+ breast cancer. We hope what we learn from the study can help us develop better treatments and figure out which treatment option(s) will be best for breast cancer patients.